AU2004206187A1 - Method for inhibition of necrosis induced by neurotrophin - Google Patents

Method for inhibition of necrosis induced by neurotrophin Download PDF

Info

Publication number
AU2004206187A1
AU2004206187A1 AU2004206187A AU2004206187A AU2004206187A1 AU 2004206187 A1 AU2004206187 A1 AU 2004206187A1 AU 2004206187 A AU2004206187 A AU 2004206187A AU 2004206187 A AU2004206187 A AU 2004206187A AU 2004206187 A1 AU2004206187 A1 AU 2004206187A1
Authority
AU
Australia
Prior art keywords
neurotrophin
bdnf
neuronal death
prevention
induced neuronal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004206187A
Other languages
English (en)
Inventor
Byoung-Joo Gwag
Sun-Hee Kim
Seok-Joon Won
Sung-Hwa Yoon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurotech Pharmaceuticals Co Ltd
Original Assignee
Neurotech Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurotech Pharmaceuticals Co Ltd filed Critical Neurotech Pharmaceuticals Co Ltd
Publication of AU2004206187A1 publication Critical patent/AU2004206187A1/en
Assigned to NEUROTECH PHARMACEUTICALS CO., LTD., GWAG, BYOUNG-JOO reassignment NEUROTECH PHARMACEUTICALS CO., LTD. Amend patent request/document other than specification (104) Assignors: BYOUNG-JOO GWAG, NEUROTECH CO., LTD
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2004206187A 2003-01-20 2004-01-20 Method for inhibition of necrosis induced by neurotrophin Abandoned AU2004206187A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2003-0003765A KR100522188B1 (ko) 2003-01-20 2003-01-20 뉴로트로핀에 의해 유도되는 세포괴사 억제 방법
KR10-2003-0003765 2003-01-20
PCT/KR2004/000119 WO2004064844A1 (en) 2003-01-20 2004-01-20 Method for inhibition of necrosis induced by neurotrophin

Publications (1)

Publication Number Publication Date
AU2004206187A1 true AU2004206187A1 (en) 2004-08-05

Family

ID=36081148

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004206187A Abandoned AU2004206187A1 (en) 2003-01-20 2004-01-20 Method for inhibition of necrosis induced by neurotrophin

Country Status (8)

Country Link
US (1) US7608585B2 (enExample)
EP (1) EP1592429A4 (enExample)
JP (1) JP2006515370A (enExample)
KR (1) KR100522188B1 (enExample)
CN (1) CN1738627A (enExample)
AU (1) AU2004206187A1 (enExample)
CA (1) CA2518888A1 (enExample)
WO (1) WO2004064844A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8241622B2 (en) 2001-07-13 2012-08-14 University Of Iowa Research Foundation Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
US6927303B2 (en) * 2002-06-19 2005-08-09 Neurotech Co., Ltd. Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same
KR20060121721A (ko) * 2005-05-23 2006-11-29 주식회사 중외제약 테트라플루오로벤질 유도체 또는 그의 염을 함유하는주사제용 조성물
CA2608553C (en) 2005-05-25 2012-04-24 Choongwae Pharma Corporation Process of preparation of substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts
JP5208369B2 (ja) * 2005-08-24 2013-06-12 ニューロテック ファーマシューティカルズ カンパニー リミテッド 神経細胞の死滅または神経機能の障害を治療するための薬学製剤及び併用療法
CA2634670A1 (en) 2005-12-30 2007-07-12 University Of Iowa Research Foundation Method of identifying compounds useful to treat neuronal degenerative diseases
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
KR100852962B1 (ko) * 2007-11-12 2008-08-20 주식회사 뉴로테크 2-하이드록시-5-페닐알킬아미노벤조산 유도체 및 이의 염의제조방법
KR101204108B1 (ko) * 2009-02-09 2012-11-22 주식회사 지엔티파마 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
CN102421430B (zh) * 2009-04-06 2014-06-25 纽若泰克制药株式会社 用于预防或治疗烧伤的药物组合物
US11702672B2 (en) 2016-02-08 2023-07-18 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
EP3426787A1 (en) 2016-03-07 2019-01-16 University of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
US12173305B2 (en) 2016-05-26 2024-12-24 University Of Iowa Research Foundation cis and trans requirements for terminal resolution of human bocavirus 1
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
CN111601643A (zh) * 2017-11-15 2020-08-28 范德比尔特大学 用于改善溶酶体功能和治疗神经退行性疾病的方法和组合物
CN110257392A (zh) * 2019-06-28 2019-09-20 西安医学院 转录后水平低氧调控基因、应用及其调控方法
AU2021233206A1 (en) * 2020-03-11 2022-10-06 Gnt Pharma Co., Ltd. Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5762922A (en) * 1994-01-31 1998-06-09 Ludwig Institute For Cancer Research Antioxidants and intracellular gluthathione raising agents for therapeutic treatments
WO1995022342A1 (en) * 1994-02-22 1995-08-24 The Syntex-Synergen Neuroscience Joint Venture Pharmaceutical formulations of ciliary neurotrophic factor
AU2000241494B2 (en) * 2000-04-19 2005-03-17 Gnt Pharma Co., Ltd. Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system

Also Published As

Publication number Publication date
US7608585B2 (en) 2009-10-27
KR100522188B1 (ko) 2005-10-18
EP1592429A1 (en) 2005-11-09
US20060135600A1 (en) 2006-06-22
CA2518888A1 (en) 2004-08-05
JP2006515370A (ja) 2006-05-25
EP1592429A4 (en) 2007-01-10
KR20040066639A (ko) 2004-07-27
WO2004064844A1 (en) 2004-08-05
CN1738627A (zh) 2006-02-22
WO2004064844A9 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
US7608585B2 (en) Compositions for inhibition of necrosis induced by a neurotrophin
Mennerick et al. Neural activity and survival in the developing nervous system
Jantzie et al. Erythropoietin attenuates loss of potassium chloride co-transporters following prenatal brain injury
Bai et al. Attenuation of Pb-induced Aβ generation and autophagic dysfunction via activation of SIRT1: Neuroprotective properties of resveratrol
Beghi et al. The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure
Zeng et al. Roles of p75NTR in the pathogenesis of Alzheimer's disease: a novel therapeutic target
Rahi et al. Understanding abnormal SMO-SHH signaling in autism spectrum disorder: potential drug target and therapeutic goals
Escames et al. The role of mitochondria in brain aging and the effects of melatonin
Prajapati et al. The role of Smo-Shh/Gli signaling activation in the prevention of neurological and ageing disorders
US20150265554A1 (en) Treatment of MeCP-2 Associated Disorders
WO2003082216A2 (en) Neuroprotectant methods, compositions, and screening methods thereof
JP2006515370A6 (ja) 神経細胞死滅を治療するための方法及び組成物
Molina-Salinas et al. Prolactin-induced neuroprotection against excitotoxicity is mediated via PI3K/AKT and GSK3β/NF-κB in primary cultures of hippocampal neurons
Zhang et al. Propofol-induced developmental neurotoxicity: from mechanisms to therapeutic strategies
US10918697B2 (en) Co-activation of mTOR and STAT3 pathways to promote neuronal survival and regeneration
He et al. Liraglutide protects neurite outgrowth of cortical neurons under oxidative stress though activating the Wnt pathway
KR20080042108A (ko) 단독의 또는 ｐｋｃ 억제제와 배합된 ｐｋｃ 활성화제의장기간 기억을 향상시키기 위한 용도
Taguchi et al. Minocycline alleviates cluster formation of activated microglia and age-dependent dopaminergic cell death in the substantia Nigra of Zitter mutant rat
HK1083686A (en) Method for inhibition of necrosis induced by neurotrophin
Zota et al. Synthetic microneurotrophins: Neurotrophin receptors for therapeutics of neurodegenerative diseases
Tomimatsu et al. Protein kinase C-mediated protection of motoneurons from excitotoxicity
Teja et al. General Introduction of Neurodegenerative Disorders
Ragupathy et al. Cell-Type Specific Mitochondrial Quality Control in the Brain: A Precise Mechanism of Neurodegeneration
Wong et al. Neuroimmunodegeneration
Volsko et al. Neuroprotective Agents: An Overview on the General Modes of Action

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE CO-APPLICANT FROM NEUROTECH CO., LTD TO NEUROTECH PHARMACEUTICALS CO., LTD.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application